Ascletis Pharmaceuticals, a US-China JV that made headlines one year ago when it announced $100 million in initial startup capital, has in-licensed China rights to its first drug candidate, an innovative RNAi molecule from Alnylam Pharma. ALN-VSP is being developed for liver cancers including hepatocellular carcinoma (HCC). Ascletis will have exclusive rights for ALN-VSP in China, Hong Kong, Macau and Taiwan. Ascletis will retain rights to the drug for the rest of the world. More details... Stock Symbol: (NSDQ: ALNY) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});